CME webcourse details new therapies, guidelines for managing ulcerative colitis
Ulcerative colitis (UC) is a chronic inflammatory bowel disease that has a severe impact on patients’ physical and psychosocial health and quality of life. Although UC is not associated with increased mortality, it is a progressive disease that requires early and effective treatment to control gastrointestinal inflammation and prevent long-term damage to the GI tract. To familiarize clinicians with recently approved targeted therapies and with the latest guidelines for managing patients with UC, the Potomac Center for Medical Education and Rockpointe offer a free CME webcourse that is available until Oct. 27, 2022.
Ulcerative colitis affects the colonic mucosa and submucosa and involves all or part of the colon. One-third of patients have extensive disease (affecting more than half the colon), and 15% have aggressive disease (become ill rapidly and have systemic symptoms). Symptoms include tenesmus, defecation urgency, bloody diarrhea, abdominal pain, and fatigue. Extraintestinal manifestations most commonly affect the joints, skin, eyes, and liver. Almost half of UC patients require hospitalization at some point.
TNF inhibitors have been the mainstay of treatment for many years, but more recently several novel targeted therapies have been approved for moderate-to-severe UC. These agents target the underlying mechanisms of UC pathogenesis and result in long-term clinical remission and improvement of symptoms for many patients. Ulcerative Colitis: The Role of Targeted Therapy is a 1.25-hour-long CME webcourse designed to provide gastroenterologists with information on the immunopathology of UC, the efficacy and safety of more recently approved targeted therapies, and the latest guidelines for management of patients with UC.
At the program’s conclusion, participants should be able to:
· Discuss the immunopathogenesis of ulcerative colitis.
· Assess the efficacy and safety of newer targeted agents approved to manage moderate-to-severe ulcerative colitis.
· Incorporate recommendations from recent evidence-based guidelines when developing management plans for patients with moderate-to-severe ulcerative colitis.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education (PCME) and Rockpointe.
PCME, which is accredited by the ACCME to provide continuing medical education for physicians, designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™.
There is no fee for this activity, which is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc. To receive credit, participants must register, view the CME activity in its entirety, and then complete the post-test, with a score of 75% or better, and evaluation. The estimated time for completion of this activity is 1.25 hours. To receive a certificate, participants must demonstrate mastery of the presented material via the post-test. Participants are allowed to take the post-test multiple times.
Through effective accredited continuing education, Rockpointe, a leader in educational programming with more than 26 years of experience, strives to improve and advance the quality of patient care. Its educational programs have been at the forefront of new issues in healthcare, including implementing MIPS, combatting the nation’s opioid and COVID-19 crises, recognizing issues with vaping, and utilizing technical advances in care. Sign up for Rockpointe’s CME course catalog and view a list of current educational opportunities, including on-demand webcourse offerings and live webinars, at www.rockpointe.com.
As part of its commitment to quality, Rockpointe works to inform the continuing-education community of significant quality-improvement issues through news and analysis on Policy & Medicine, which offers a daily look at legal, regulatory, and compliance issues affecting the pharmaceutical and device industry. Rockpointe also publishes Policy & Medicine Compliance Update, a monthly publication that provides a concise update on compliance issues facing the life science industry and goes in-depth into important cases, laws, and regulations in straightforward articles. At Rockpointe, education equals quality.
To view Ulcerative Colitis: The Role of Targeted Therapy, click here.